Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,575.78
(
0.16%
)
US TECH 100
29,476.80
(
0.18%
)
Dow Jones
50,956.73
(
0.57%
)
Brent Oil
90.95
(
-1.34%
)
Bitcoin
73,817.96
(
0.38%
)
News Focus
News Focus
Post# of 257657
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123037
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 222673

Sunday, 03/31/2019 7:41:27 PM

Sunday, March 31, 2019 7:41:27 PM

Post# of 257657
Notable observation from NTGN update:

https://www.globenewswire.com/news-release/2019/03/31/1790265/0/en/Neon-Therapeutics-Presents-Updated-Data-from-Ongoing-Phase-1b-NT-001-Clinical-Trial-of-Personal-Neoantigen-Vaccine-NEO-PV-01-at-AACR-2019-Annual-Meeting.html

Several metrics that typically correlate with patient response to checkpoint inhibitors, including tumor mutation burden and tumor PD-L1, were not correlated with [durable clinical benefit] in this analysis…

Reminder: As noted earlier in this thread (#msg-144385069), this phase-1 trial does not test NEO-PV-01 monotherapy.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today